GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genenta Science SPA (NAS:GNTA) » Definitions » Debt-to-EBITDA

Genenta Science SPA (Genenta Science SPA) Debt-to-EBITDA : 0.00 (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Genenta Science SPA Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Genenta Science SPA's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.00 Mil. Genenta Science SPA's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.00 Mil. Genenta Science SPA's annualized EBITDA for the quarter that ended in Dec. 2023 was $-10.71 Mil. Genenta Science SPA's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was 0.00.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Genenta Science SPA's Debt-to-EBITDA or its related term are showing as below:

GNTA's Debt-to-EBITDA is not ranked *
in the Biotechnology industry.
Industry Median: 1.36
* Ranked among companies with meaningful Debt-to-EBITDA only.

Genenta Science SPA Debt-to-EBITDA Historical Data

The historical data trend for Genenta Science SPA's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genenta Science SPA Debt-to-EBITDA Chart

Genenta Science SPA Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
- - - - -

Genenta Science SPA Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only - - - - -

Competitive Comparison of Genenta Science SPA's Debt-to-EBITDA

For the Biotechnology subindustry, Genenta Science SPA's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genenta Science SPA's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genenta Science SPA's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Genenta Science SPA's Debt-to-EBITDA falls into.



Genenta Science SPA Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Genenta Science SPA's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0 + 0) / -12.748
=0.00

Genenta Science SPA's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0 + 0) / -10.712
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is two times the quarterly (Dec. 2023) EBITDA data.


Genenta Science SPA  (NAS:GNTA) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Genenta Science SPA Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Genenta Science SPA's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Genenta Science SPA (Genenta Science SPA) Business Description

Traded in Other Exchanges
Address
Via Olgettina No. 58, Milan, ITA, 20132
Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's lead product includes Temferon - a product to treat glioblastoma multiforme, a solid tumor affecting the brain, and TEMs -Immuno-Gene Therapy.